Jackie joined Foghorn as VP of regulatory affairs in July 2020. She has more than 30 years of pharmaceutical development experience, with a focus in clinical and global regulatory strategy.
Prior to joining Foghorn, Jackie was the senior director of regulatory affairs at Agios Pharmaceuticals. Over a period of 7 years at Agios Pharmaceuticals, Jackie built a strategic-focused regulatory team that was responsible for IND applications supporting 8 investigational products to treat hematologic malignancies, solid tumors and rare genetic diseases and for the approved marketing application for TIBSOVO®. Prior to Agios, she spent 10 years as an independent consultant providing regulatory support and strategic assessments to a variety of pharmaceutical companies. Preceding this, Jackie contributed to the initial build of regulatory and clinical teams at Millennium Pharmaceuticals, LeukoSite and Vertex Pharmaceuticals; she started her pharmaceutical career in the chemistry labs and then on the clinical team at the R.W. Johnson Pharmaceutical Research Institute. During her career, Jackie provided lead regulatory support for the approval of CAMPATH® and actively advanced the clinical development (IDHIFA®, VELCADE®, ENTYVIO®, LEVAQUIN®, FLOXACIN®).
Jackie earned a master’s degree in medicinal chemistry and a bachelor’s degree in pharmacy from Duquesne University.